Howard Berman - 18 Jun 2026 Form 4 Insider Report for Atea Pharmaceuticals, Inc. (AVIR)

Reporting relationship: Director
Issuer ticker: AVIR
Reported as of: 18 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jun 2026, 17:00:12 UTC
Prior SEC filing: 26 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Andrea Corcoran, as Attorney-in-Fact for Howard Berman

Key filing fact

Howard Berman filed Form 4 for Atea Pharmaceuticals, Inc. (AVIR) on 23 Jun 2026.

Key facts

This page summarizes Howard Berman's Form 4 filing for Atea Pharmaceuticals, Inc. (AVIR).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 23 Jun 2026, 17:00.

Change

Previous filing in this sequence was filed on 26 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001952986 Primary reporting owner

Berman Howard

Relationship: Director
Address: 225 FRANKLIN STREET, SUITE 2100, BOSTON
Signature: /s/ Andrea Corcoran, as Attorney-in-Fact for Howard Berman
Signature date: 23 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AVIR transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +26,700
Change %
Price: $0.000000^*
Shares after: 26,700
Date: 18 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 26,700
Exercise price
Footnotes: F1, F2

AVIR transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +37,700
Change %
Price: $0.000000^*
Shares after: 37,700
Date: 18 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 37,700
Exercise price: $4.36
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Footnote F2

The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date.

Footnote F3

The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026, such that the option shall be fully vested on June 18, 2027, subject to the Reporting Person's continued service through each such vesting date.